Sun Pharma receives warning letter for Halol facility

Leading pharma company, Sun Pharmaceutical Industries has said that it has received a warning letter from the USFDA as a result of the September 2014 inspection, for its facility located at Halol, Gujarat in India.

Cipla launches generic hepatitis C drug 'Hepcvir-L' in India

Cipla has launch of generic tablets used for treating of hepatitis C under the brand name ' Hepcvir-L' costing Rs25,000 for a bottle of 28 tablets in India.

M&M to launch new compact SUV KUV1OO on Jan 15

M&M to launch new compact SUV i.e KUV1OO on 15th January; positive for the company

Mahindra & Mahindra (M&M) has revealed the looks of its upcoming mini SUV christened KUV1OO (codename S101).

The name stands for Cool SUV, targeting the youth segment and it would be launched on 15th January.

Titagarh hopes to secure 25% of Railways wagon order

The Indian Railways has put out a tender for 14,777 wagons, bids for which have to be submitted by January 12. The company plans to bid for the entire tender and is hopeful of securing about 25% of the total order.

Glenmark enters into settlement agreement with Forest Lab

Leading pharma company, Glenmark Pharmaceuticals has announced that that it has entered into a settlement agreement with Forest Laboratories, LLC, Forest Laboratories Holdings, and Royalty Pharma collection trust to settle and dismiss the outstanding patent litigation related to Glenmark’s abbreviated new drug application for Milnacipran Hydrochloride 12.5 milligram, 25 milligram, 50 milligram, and 100 milligram tablets, the generic version of Forest’s Savella®.

'Under the terms of the settlement agreement, Glenmark will have the option to market and distribute its Milnacipran Hydrochloride tablets or an authorized generic version of Savella® tablets,”